Home > Press > NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza
Abstract:
Studies being presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009
NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.
Data from both studies will be presented on Sunday, September 13th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:
Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets
Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine
NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company's development programs for its vaccine, dermatological and anti-infective programs will be available.
####
About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
About NanoBio’s Vaccine Platform
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcus, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen sparing qualities; cross-protection against strains not included in the vaccine; ability to adjuvant multiple antigen types without inducing inflammation; thermal stability of the vaccine; and removing the need for needles.
NanoBio Corp. announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered intranasally. This Phase 1 study is ongoing.
For more information, please click here
Contacts:
Telephone: 734.302.4000
Fax: 734.302.9150
Copyright © NanoBio Corp.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
New method in the fight against forever chemicals September 13th, 2024
Energy transmission in quantum field theory requires information September 13th, 2024
Breakthrough in proton barrier films using pore-free graphene oxide: Kumamoto University researchers achieve new milestone in advanced coating technologies September 13th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Nanomedicine
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Announcements
New discovery aims to improve the design of microelectronic devices September 13th, 2024
New method in the fight against forever chemicals September 13th, 2024
Nanobiotechnology
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||